Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
Authors
Stefania Napolitano
Università Degli Studi Della Campania, “Luigi Vanvitelli”, Napoli, Italy;
Stefania Napolitano , Vincenzo De Falco , Giulia Martini , Lucia Esposito , Vincenzo Famiglietti , Erika Martinelli , Davide Ciardiello , Francesca Marrone , Antonio Avallone , Claudia Cardone , Alfonso De Stefano , Vincenzo Montesarchio , M. Giulia Zampino , Roberto Bordonaro , Mario Scartozzi , Daniele Santini , Massimo Di Maio , Fortunato Ciardiello , Teresa Troiani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05468892
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 129)
DOI
10.1200/JCO.2023.41.4_suppl.129
Abstract #
129
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
First Author: John H. Strickler
![PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. .](https://d201v5jt9ylckg.cloudfront.net/102/6682/61160/61160_poster_pv.jpg)
First Author: J. Maurel
Poster
2020 Gastrointestinal Cancers Symposium
A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.
First Author: Jingquan Jia
Poster
2019 Gastrointestinal Cancers Symposium
Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial.
First Author: Yoshihito Ohhara